Ami Organics IPO - Subscribe For Listing Gains: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal's IPO Report
Ami Organics Ltd., is focused towards manufacturing of advanced pharma intermediates for regulated/generic active pharma ingredients and new chemical entities and key starting material for agrochemical and fine chemicals.
Ami Organics has built a strong and diversified portfolio of 450 plus pharma intermediates (88% revenue share in FY21) across 17 therapeutic areas which are high-growth and high margin, and commands significant market share both in India and globally.
It is one of the major manufacturers of pharma intermediates like Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban of which first two contributed ~44% of FY21 revenues.
FY21-end, the company completed the acquisition of Gujarat Organics Ltd., which enhanced its capacity by 3,600 million tonne per annum to 6060 million tonne per annum.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.